Enhancing immunotherapy treatment response with a novel molecular glue degrader of the corest complex in triple-negative breast cancer
Active Project Grant Awarded Last action
- Award ID
- HT9425261E465
- Recipient
-
University Of Florida UEI NNFQH1JAPEP3
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $996,470
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date 0% complete
- Place of performance
- Gainesville, FL 32611, USA
Award details come from USAspending.gov.
About this award
The Defense Health Agency awarded the University of Florida $996,470 under the Military Medical Research and Development program (CFDA 12.420) on November 1, 2026, to enhance immunotherapy treatment response in triple-negative breast cancer through development of a novel molecular glue degrader of the COREST complex.
Work is performed in Gainesville, Florida from November 1, 2026 through October 31, 2029. The University of Florida's Division of Sponsored Research serves as recipient, administering the project grant.
Quick answers
Who received award HT9425261E465?
HT9425261E465 was awarded to University Of Florida by Defense Health Agency (Department of Defense) on November 1, 2026.
How much is award HT9425261E465 worth?
$996,470 has been obligated on HT9425261E465.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award